EMEA-001912-PIP01-15
Key facts
Active substance |
Angiotensin II (LJPC-501)
|
Therapeutic area |
Other
|
Decision number |
P/0253/2016
|
PIP number |
EMEA-001912-PIP01-15
|
Pharmaceutical form(s) |
Solution for infusion
|
Condition(s) / indication(s) |
Treatment of catecholamine-resistant hypotension associated with distributive shock
|
Route(s) of administration |
Intravenous use
|
Contact for public enquiries |
La Jolla Pharmaceutical Company, Inc.
United States
Tel. +1 8584336908 |
Decision type |
RP: decision refers to a refusal on a proposed Paediatric Investigation Plan
|